Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman
San Francisco, California--(Newsfile Corp. - August 7, 2025) - A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune (NADAQ: REPL) securities between November 22, 2024 and July 21, 2025.The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA)...
2025-08-07 9:43 AM EDT
HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending -- Hagens Berman
San Francisco, California--(Newsfile Corp. - August 7, 2025) - On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized GLP-1 component, a medication the company compounds to treat weight loss.This disclosure comes as the company previously experienced a sell-off in its shares which triggered a securities class action lawsuit tied to a cancelled collaboration with...
2025-08-07 9:29 AM EDT
RCKT 4-DAY DEADLINE ALERT: FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action - Hagens Berman
San Francisco, California--(Newsfile Corp. - August 7, 2025) - When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder.Since the May 27 announcement,...
2025-08-07 9:25 AM EDT
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over "Inflated Guidance" - Hagens Berman
San Francisco, California--(Newsfile Corp. - August 5, 2025) - Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results.The company, a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks...
2025-08-05 6:39 PM EDT
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman
San Francisco, California--(Newsfile Corp. - August 5, 2025) - On July 16, 2025, Sarepta Therapeutics (NASDAQ: SRPT) announced a major restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million. The company also agreed with the FDA to include a black box warning of acute liver injury and acute liver failure in Sarepta's ELEVIDYS label. ELEVIDYS is the company's gene therapy drug intended to treat a limited category of...
2025-08-05 6:28 PM EDT
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy(R) - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 31, 2025) - On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. The cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated...
2025-07-31 5:11 PM EDT
Centene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over "Inflated Guidance" Pending - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 29, 2025) - Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results.The company, a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks...
2025-07-29 3:26 PM EDT
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 29, 2025) - A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025.The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA)...
2025-07-29 3:19 PM EDT
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 29, 2025) - When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder.Since the May 27 announcement,...
2025-07-29 3:05 PM EDT
Sarepta Therapeutics (SRPT) Tanks 36% After 3d Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman
San Francisco, California--(Newsfile Corp. - July 25, 2025) - On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again - this time, shares closed down $7.89 (-36%) - after the company reported the death of a third patient who was being treated with one of its experimental gene therapy drugs.The development comes in the wake of a securities class action styled Dolgicera v. Sarepta Therapeutics, Inc. et al., No. 1:25-cv-05317 (S.D.N.Y.),...
2025-07-25 4:42 PM EDT
Hims & Hers Health, Inc. (HIMS) Alleged "Deceptive" Marketing of Wegovy(R) Triggers Securities Class Actions - HIMS Investors with Losses Encouraged to Contact Hagens Berman
San Francisco, California--(Newsfile Corp. - July 25, 2025) - On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. The cases seeks to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated...
2025-07-25 4:38 PM EDT
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over "Inflated Guidance" - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 24, 2025) - Healthcare giant Centene Corporation (NYSE: CNC), a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934.National shareholders rights firm Hagens...
2025-07-24 4:23 PM EDT
BellRing Brands (BRBR) Faces Investor Scrutiny Amid Upcoming Retailer Destocking, Share Price Decline; BRBR Investors with Substantial Losses and Persons with Knowledge Encouraged to Contact Hagens Berman
San Francisco, California--(Newsfile Corp. - July 23, 2025) - On May 6, 2025 investors in BellRing Brands, Inc. (NYSE: BRBR) saw the price of their shares decline about 19% after BellRing announced during its Q2 2025 earnings call that it anticipated Q3 2025 reduction in retailer inventory levels.This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether BellRing Brands may have violated the securities laws concerning the company's sales practices. The firm urges BellRing...
2025-07-23 6:01 PM EDT
The J.M. Smucker Company (SJM) Faces Investor Scrutiny After Announcing The Second Hostess-Related Impairments In About 3 Months - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 23, 2025) - On June 10, 2025 investors in The J.M. Smucker Company (NYSE: SJM) saw the price of their shares decline over 15% after the company announced disappointing Q4 2025 financial results.This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether SJM may have violated the securities laws concerning the propriety of its statements about the benefits of the Hostess Brands acquisition. The firm urges SJM investors...
2025-07-23 5:57 PM EDT
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 22, 2025) - When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder.Since the May 27 announcement,...
2025-07-22 12:38 PM EDT
Hims & Hers Health, Inc. (HIMS) Alleged "Deceptive" Marketing of Wegovy(R) Triggers Securities Class Actions - HIMS Investors with Losses Encouraged to Contact Hagens Berman
San Francisco, California--(Newsfile Corp. - July 22, 2025) - On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. The cases seeks to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated...
2025-07-22 12:32 PM EDT
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over "Inflated Guidance" - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 22, 2025) - Healthcare giant Centene Corporation (NYSE: CNC), a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934.National shareholders rights firm Hagens...
2025-07-22 12:22 PM EDT
CTO Realty Growth, Inc. (CTO) Shares Decline Amid Wolfpack Report - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 21, 2025) - On June 25, 2025 investors in CTO Realty Growth, Inc. (NYSE: CTO) saw the price of their shares significantly decline after Wolfpack Research published CTO: The B. Riley Of REITS, accusing CTO of misleading investors about its dividend sustainability and engaging in dubious financial activities.This report has prompted national shareholders rights firm Hagens Berman to open an investigation into the allegations and whether CTO may have violated the securities laws....
2025-07-21 12:19 PM EDT
KBR, Inc. (KBR) Faces Investor Scrutiny After TRANSCOM Terminated Contract, Stock Price Decline - KBR Investors with Substantial Losses Encouraged to Contact Hagens Berman
San Francisco, California--(Newsfile Corp. - July 21, 2025) - On June 20, 2025 investors in KBR, Inc. (NYSE: KBR) saw the price of their shares decline over 7% after the company announced that the Department of Defense U.S. Transportation Command ("TRANSCOM") cancelled its global household goods contract ("contract") awarded to HomeSafe Alliance LLC, a KBR led joint venture.This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether KBR may have violated the securities laws...
2025-07-21 12:17 PM EDT
Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report - Hagens Berman
San Francisco, California--(Newsfile Corp. - July 21, 2025) - Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research-a newly formed investigative group led by analysts who previously worked at the renowned Hindenburg Research. Despite Abacus's public denials and the announcement of a $20 million share repurchase program, investor confidence remains shaken, with shares now down more than 36% over the past month.Prominent law...
2025-07-21 12:14 PM EDT